Parkinova – Thermoresponsive Nasal Gel
Innovator ID
SNDMAC015
Intranasal thermoresponsive Rasagiline gel enhancing brain delivery for Parkinson’s treatment, improving efficacy, reducing side effects, and supporting better patient adherence.
Parkinson’s disease affects motor function due to progressive degeneration of dopaminergic neurons. Oral Rasagiline Mesylate, a commonly prescribed drug, has low brain bioavailability because it undergoes significant first-pass metabolism. As a result, patients require higher doses, which increases systemic side effects. Injectable alternatives are invasive and reduce long-term treatment adherence. Patients struggle with tremors, stiffness, and slow mobility, making dosage precision difficult. There is a need for a non-invasive, controlled-release, targeted delivery system that improves brain drug absorption, reduces systemic toxicity, and enhances patient compliance for better disease management.
Parkinova uses a thermoresponsive chitosan-based intranasal gel to deliver Rasagiline directly to the brain, bypassing first-pass metabolism. The gel transforms from liquid to gel inside the nasal cavity, increasing residence time and improving brain uptake, offering a non-invasive, patient-friendly, and more effective treatment option for Parkinson’s disease.
Primary customers include Parkinson’s patients who require easier, safer long-term medication. Healthcare providers such as neurologists, neurology hospitals, rehabilitation centers, and geriatric clinics would prescribe the formulation to improve patient adherence and symptom control. Pharmaceutical companies and biotech firms are key partners for manufacturing, licensing, and scaling. Caregivers benefit from simplified administration and improved patient comfort.
Parkinova improves brain drug delivery, enhances therapeutic effect, reduces systemic side effects, and promotes better patient adherence compared to oral or injectable therapies. Hospitals and neurologists benefit from improved disease management outcomes and reduced relapse risks. Pharma partners gain a scalable drug delivery platform that can be extended to other CNS drugs. Patients experience easier administration, reduced discomfort, and better day-to-day functional control. The innovation delivers clinical value, economic efficiency, and improved quality of life, making it a strong, sustainable healthcare solution.
We Would Require Support In the Following :
Technical and Product Development Support; Funding and Financial Assistance; Infrastructure and Prototyping Facilities; Networking, Collaboration, and Investor Connect
Capital to achieve the desired outcome, we would require
₹150–200 L, detailed
And would be required for
Prototype Development Support; Research, Design & Validation Funding; Business Model & Market Access Support; Technology and Digital Infrastructure Funding; Pilot Testing and Field Trial Support
Expected Return Should Be in:
More than 3+ years